Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

ClinicalTrials.gov ID: NCT01085214

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01085214. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of AZD6244 in Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.

Study identification

NCT ID
NCT01085214
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
37 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2010 (Type not available)
Primary completion
Mar 2012 (Actual)
Completion
Mar 2012 (Actual)
Last update posted
Aug 19, 2015

2010 – 2012

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Moffitt Cancer Center Tampa Florida 33612 —
Emory University/Winship Cancer Institute Atlanta Georgia 30322 —
University of Maryland/Greenebaum Cancer Center Baltimore Maryland 21201 —
Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda Maryland 20892 —
National Institutes of Health Bethesda Maryland 20892 —
Billings Clinic Cancer Center Billings Montana 59107 —
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 —
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 —
Virginia Commonwealth University/Massey Cancer Center Richmond Virginia 23298 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01085214, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2015 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.